Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GP, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU; PRESTIGE-AF Consortium.
Veltkamp R, et al. Among authors: muller p.
Lancet. 2025 Mar 15;405(10482):927-936. doi: 10.1016/S0140-6736(25)00333-2. Epub 2025 Feb 26.
Lancet. 2025.
PMID: 40023176
Free article.
Clinical Trial.